← The Wire
TRVINasdaq
Trevi Therapeutics, Inc.
Pharmaceutical Preparations · DE · CIK 1563880
Develops and commercializes Haduvio for chronic cough in adults with lung diseases
$2.02B
Market cap
$18.63
Last close
+2.6%
1D
+5.2%
5D
2.9M
Volume
Price · last 39 sessions+29.6%
May 4L $13.24 · H $18.63Jun 29
152
Total filings
Jun 4, 2026
Last filing
12/31
Fiscal year end
SC 13GTREVI SC 13GAFeb 15, 2023SC 13GSC 13GFeb 10, 2023SC 13GSC 13GOct 7, 2022SC 13GSC 13GApr 21, 2022SC 13GSC 13GApr 21, 2022SC 13GSC 13GApr 18, 2022SC 13GMAI 13GApr 8, 2022SC 13GSC 13GMar 9, 2022SC 13GSC 13GMar 9, 2022SC 13GSC 13GFeb 14, 2022SC 13GACQUISITION OF BENEFICIAL OWNERSHIPFeb 13, 2020SC 13GSC 13GJan 31, 2020
Similar companies
Comparable business profile · signals at a glance